Among them, promoter methylation of HOPX is observed very frequently in a cancer-specific manner, and is correlated with worse long-term prognosis in esophageal squamous cell carcinoma [21], gastric cancer [14], colorectal cancer [12], pancreas cancer [15], and breast cancer [13]. Here, HOPX is linked to colorectal cancer.